Isotechnika, ILJIN autoimmune, transplant news

Isotechnika said that ILJIN's ILJIN Life Sciences Co. Ltd. subsidiary has formally withdrawn all claims for damages in the parties' pending arbitration related to the biotech's January 2011 termination of a 2010 deal related to voclosporin. The deal gave ILJIN Life Sciences rights to voclosporin in transplant and autoimmune indications in the U.S. and territories outside of Europe, Canada, Israel, South Africa, China and Taiwan. Last November, the arbitration tribunal declared the deal to be in full force and effect (see BioCentury, Nov. 22, 2010; Feb. 6, 2012 & April 2, 2012). ...